British journal of clinical pharmacology
-
Br J Clin Pharmacol · Apr 2013
Randomized Controlled TrialExenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QTc ) at therapeutic concentrations. This randomized, placebo- and positive-controlled, crossover, thorough QT study evaluated the effects of therapeutic and supratherapeutic exenatide concentrations on QTc . ⋯ These results demonstrated that exenatide, at supratherapeutic concentrations, does not prolong QTc and provide an example of methodology for QT assessment of drugs with an inherent heart rate effect.